RhumbLine Advisers’s Theriva Biologics TOVX Stock Holding History

RhumbLine Advisers’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-11	Closed	-$59K	–	2957
2017 Q1	$59K	Buy	11 +4	+57%	+$27.9K	﹤0.01%	2815
2016 Q4	$46K	Sell	7 -2	-22%	-$20.5K	﹤0.01%	2830
2016 Q3	$140K	Buy	9 +1	+13%	+$15K	﹤0.01%	2759
2016 Q2	$126K	Buy	+8	New	+$151K	﹤0.01%	2876

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

RhumbLine Advisers's TOVX Position: Q2 2017 in Review

RhumbLine Advisers sold out of Theriva Biologics (TOVX) in Q2 2017, closing a stake of 11 shares — an estimated $59K sold.

RhumbLine Advisers first reported a position in TOVX in Q2 2016 and held it in 4 quarters. The position peaked at $140K in Q3 2016. 53 funds tracked by Wall St. Rank hold TOVX as of Q2 2017.

RhumbLine Advisers reported no remaining Theriva Biologics position as of Q2 2017 after selling out during the quarter.
RhumbLine Advisers sold 11 Theriva Biologics shares in Q2 2017, an estimated $59K.
RhumbLine Advisers first reported a position in Theriva Biologics in Q2 2016 and held it in 4 quarters.
RhumbLine Advisers's Theriva Biologics position peaked at $140K in Q3 2016.
53 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2017.

Based on RhumbLine Advisers's 13F filing for Q2 2017, filed 2 Aug 2017.